NADA has been shown to inhibit breast cancer cell growth in vitro and in vivo [37], in human osteosarcoma, lymphoma, and leukemia cell lines [38] and in colorectal carcinoma cells via activation of CB1R [23], while the inhibition of cell growth of neuroblastoma cells was mediated by TRPV1 receptor activation [39]. This evidence concerns the gene CNR1 and breast carcinoma.